Compare Procter & Gamble Co (PG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Procter & Gamble Co vs Sanofi SA — how do they compare? Procter & Gamble Co trades at $149.52 (market cap $344.87B), while Sanofi SA trades at $43.89 (market cap $104.85B). The key difference: Procter & Gamble Co is far larger — about 3.3× Sanofi SA's market cap, and Sanofi SA pays the higher dividend (5.53%). Which is the better fit depends on your goals.
| PG | SNY | |
|---|---|---|
Market Cap | $344.87B | $104.85B |
Volume | 6,423,436 | — |
Sector | Consumer Staples | Health |
52-Week High | $167.18 | $52.34 |
52-Week Low | $138.10 | $41.33 |
Enterprise Value | $370.34B | $121.38B |
Dividend Yield | 2.94% | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Procter & Gamble (PG) trades at $149.15, showing minimal daily movement. The stock exhibits neutral technical signals with support near $147 and resistance at $150. Fundamentally, PG maintains stable revenue near $84.3 billion and strong net income margins above 19%, supported by consistent earnings beats. Recent news highlights its dividend reliability amid market volatility, with a 69-year track record of increases. Analyst consensus is bullish with a $160.50 price target, though valuation multiples trade at premiums to peers.
PG offers steady growth with dividend safety but faces near-term headwinds from premium valuations and modest revenue expansion. Upside depends on execution of supply chain efficiencies and sustained consumer demand. Risks include competitive pressures and economic sensitivity. Institutional ownership trends show mixed positioning, reflecting cautious optimism.
SNY trades at $43.76, down 2.02% today, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q2 2026 results pending. Revenue grew to $46.72B in 2025, with net income margin improving to 16.72%. Recent positive developments include FDA approval for Sarclisa's wearable injector and EU approval for Cenrifki in multiple sclerosis.
Outlook remains positive with analyst consensus leaning toward buy/hold, though regulatory scrutiny in the EU presents near-term risk. The stock offers a solid dividend yield with the upcoming $2.42 payment. Valuation metrics like P/E of 19.5 and P/B of 1.27 suggest reasonable pricing relative to peers, supported by robust cash flow from operations of $10.75B.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
